think about the potential..19 Feb 2019 10:20
VAL201: The company continues to recruit appropriate patients for the concluding part of the trial, with completion expected in H1 2019.
'Given the clinical progress made with VAL201 and VAL401 and the company’s approach to outlicensing, we believe that ValiRx should be close to agreeing a deal with potential commercial partners in the form of big pharma companies. To illustrate the potential value here, many recent deals for Phase II therapeutic candidates have run into the many hundreds of millions of dollars, representing many multiples of ValiRx’s current market cap.'